CROI 2013: Transmitted Antiretroviral Drug Resistance Holds Steady at 16% [VIDEO]


Approximately 1 in 6 analyzed HIV sequences showed evidence of antiretroviral drug resistance, with NNRTIs being particularly vulnerable, according to a CDC analysis presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

David Kim and colleagues from the Centers for Disease Control and Prevention looked at trends in transmitted HIV drug resistance-associated mutations among more than 18,000 newly infected people in the U.S. during 2007-2010, using a database of known resistance mutations.

They found that approximately 16% of tested sequences contained transmitted resistance mutations associated with any of the 3 first antiretroviral drug classes (nucleoside/nucleotide reverse transcriptase inhibitors, NNRTIs, and protease inhibitors), including about 2% with 2-class resistance and 0.5% with 3-class resistance. The proportion rose slightly from about 15% in 2007 to nearly 17% in 2010.

"These findings warrant continued monitoring of [transmitted drug resistance mutations] and further studies to assess the adverse impact that the increasing NNRTI-associated [transmitted drug resistance mutations] may have on HIV-1 treatment," the researchers concluded.

Kim summarized his results at a March 6, 2013, CROI press conference on Advances in ART and Anti-Hepatitis C Therapy.

[David Kim speaks at CROI 2013 press conference, Atlanta, March 6, 2013]



D Kim, R Ziebell, N Saduvala, et al. Trend in Transmitted HIV-1 ARV Drug Resistance-associated Mutations: 10 HIV Surveillance Areas, US, 2007-2010. 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013). Atlanta, March 3-6, 2013. Abstract 149.